ReviewHaemophilia : the official journal of the World Federation of Hemophilia2016
Von Willebrand factor for menorrhagia: a survey and literature review.
Review in Haemophilia : the official journal of the World Federation of Hemophilia, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02606045 (Prospective, Randomized, Crossover Trial Comparing Recombinant Von Willebrand Factor), which is not on this map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Prospective, Randomized, Crossover Trial Comparing Recombinant Von Willebrand Factor (rVWF) vs. Tranexamic Acid (TA) to Minimize Menorrhagia in Women With Von Willebrand Disease: The VWD Minimize Study
Who cites it
22 citing papers in PubMed, 47 citations in OpenAlex.
- Recombinant von Willebrand factor and tranexamic acid for heavy menstrual bleeding in patients with mild and moderate von Willebrand disease in the USA (VWDMin): a phase 3, open-label, randomised, crossover trial.The Lancet. Haematology · 2023Trial
- Call to action: identifying an underlying bleeding disorder in adolescents with heavy menstrual bleeding.Research and practice in thrombosis and haemostasis · 2026Review
- Von Willebrand disease: A century of progress.Research and practice in thrombosis and haemostasis · 2026Review
- Gynecologic and obstetric management of girls and women with von Willebrand disease.Haematologica · 2026Review
- Prophylaxis for von Willebrand disease: Is it time for parity with established practice in hemophilia A?Therapeutic advances in hematology · 2026Review
- Global estimation of the bleeding episodes treatable with desmopressin in von Willebrand disease and hemophilia A.Haematologica · 2025Review
- Efficacy of regular prophylaxis with a plasma-derived von Willebrand factor/factor VIII concentrate with a 1:1 activity ratio in reducing heavy menstrual bleeding in girls/women with von Willebrand disease.AJOG global reports · 2025Article
- Prevalence of heavy menstrual bleeding, iron deficiency, iron deficiency anemia, and treatment in women with von Willebrand disease-a cohort study.Research and practice in thrombosis and haemostasis · 2025Article
- von Willebrand disease.Nature reviews. Disease primers · 2024Review
- Primary Hemostasis Disorders as a Cause of Heavy Menstrual Bleeding in Women of Reproductive Age.Journal of clinical medicine · 2023Review
- Reproductive Tract Bleeding in Adolescent and Young Adult Females with Inherited Bleeding Disorders: An Underappreciated Problem.Journal of pediatric and adolescent gynecology · 2022Review
- Whole-exome analysis of adolescents with low VWF and heavy menstrual bleeding identifies novel genetic associations.Blood advances · 2022Article
- Bleeding patterns in patients before and after diagnosis of von Willebrand disease: Analysis of a US medical claims database.Haemophilia : the official journal of the World Federation of Hemophilia · 2022Article
- Hemostatic profile detailing in apparent VWD cases: A cross sectional study.Saudi journal of biological sciences · 2021Article
- Managing women-specific bleeding in inherited bleeding disorders: A multidisciplinary approach.Haemophilia : the official journal of the World Federation of Hemophilia · 2021Article
- Case-based discussion on the implications of exogenous estrogens in hemostasis and thrombosis: the hematologist's view.Hematology. American Society of Hematology. Education Program · 2019Article
- Evaluation and management of heavy menstrual bleeding in adolescents: the role of the hematologist.Hematology. American Society of Hematology. Education Program · 2018Review
- Current challenges in the diagnosis and management of patients with inherited von Willebrand's disease in Italy: an Expert Meeting Report on the diagnosis and surgical and secondary long-term prophylaxis.Blood transfusion = Trasfusione del sangue · 2018Review
- Prevalence of Bleeding Symptoms among Adolescents and Young Adults in the Capital City of Saudi Arabia.Advances in hematology · 2018Article
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 9 institutions in 1 country.
Funding
Abstract
backgroundvon Willebrand disease (VWD) is the most common congenital bleeding disorder. In women, menorrhagia is the most common bleeding symptom, and is disabling with iron deficiency anaemia, high health cost and poor quality of life. Current hormonal and non-hormonal therapies are limited by ineffectiveness and intolerance. Few data exist regarding von Willebrand factor (VWF), typically prescribed when other treatments fail. The lack of effective therapy for menorrhagia remains the greatest unmet healthcare need in women with VWD. Better therapies are needed to treat women with menorrhagia.
methodsWe conducted a survey of US haemophilia treatment centres (HTCs) and a literature review using medical subject heading (MeSH) search terms 'von Willebrand factor,' 'menorrhagia' and 'von Willebrand disease' to assess the use of VWF in menorrhagia. Analysis was by descriptive statistics.
resultsOf 83 surveys distributed to HTC MDs, 20 (24.1%) provided sufficient data for analysis. Of 1321 women with VWD seen during 2011-2014, 816 (61.8%) had menorrhagia, for which combined oral contraceptives, tranexamic acid and desmopressin were the most common first-line therapies for menorrhagia, whereas VWF was third-line therapy reported in 13 women (1.6%). Together with data from 88 women from six published studies, VWF safely reduced menorrhagia in 101 women at a dose of 33-100 IU kg(-1) on day 1-6 of menstrual cycle.
conclusionsThis represents the largest VWD menorrhagia treatment experience to date. VWF safely and effectively reduces menorrhagia in women with VWD. A prospective clinical trial is planned to confirm these findings.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.